Food science & nutrition · 2026
Salidroside Ameliorates Polycystic Ovary Syndrome in Mice by Regulating the AKT/NF-κB/NLRP3-HAS2 Axis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Jing-Hang, Shi Shu-Ming, Liu Li-Ying, He Yu-Yan, Jia Guan-Lin, Qu Lin-Yi, Chi Zhi-Chao, Leng Jia-Hui, Xu Hong-Jie, Lan Tian, Yan Dong-Lei, Kong Il-Keun, Yu Xian-Feng, Zhang Ming-Jun, Jin Yong-Xun
Аннотация
Salidroside, a bioactive compound from Rhodiola rosea, shows potential in managing polycystic ovary syndrome (PCOS), a common endocrine-metabolic disorder. This study explored its therapeutic effects and mechanisms using a dehydroepiandrosterone (DHEA)-induced PCOS mouse model and granulosa cells (GCs). Salidroside was found to restore estrous cyclicity, improve ovarian morphology, and rebalance serum hormone levels. Mechanistically, it suppressed ROS-mediated AKT/NF-κB signaling, inhibited NLRP3 inflammasome activation, and reduced proinflammatory cytokines. Network pharmacology and molecular docking identified AKT as a core target, validated by CETSA and DARTS assays. Furthermore, salidroside disrupted NLRP3-driven latent TGF-β1 (LAP-TGFβ1) activation, downregulated TGF-β-SMAD2/3 signaling, and attenuated ovarian fibrosis along with abnormal hyaluronan synthase 2 (HAS2) expression. These results highlight salidroside as a promising natural candidate for alleviating PCOS through coordinated anti-inflammatory and antifibrotic mechanisms.